Jason Starr, DO, discusses the importance of molecular residual disease within the cancer treatment landscape.
News Network
Advertisement
Advertisement
Trending on AJMC
1
Shifts in Colorectal Cancer Screening Trends After COVID-19
2
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
3
Challenges, Opportunities in Implementing the MDPP: Melanie T. Turk, PhD, RN
4
3 New Study Findings to Look Out for at Menopause Society 2025
5
